Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 10, 2026, 4:32 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 45 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Fat Emulsion 20% Clear all
Completed Not applicable Interventional Accepts healthy volunteers Results available

Training Effects on Skeletal Muscle Fatty Acid Metabolism

NCT00786487
View directory record Official record
Conditions
Healthy Volunteers
Interventions
20% lipid infusion, glycerol
Drug
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years to 45 Years
Enrollment
33 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2014
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Jul 22, 2015 · Synced Sep 10, 2026, 4:32 PM EDT
Completed Phase 3 Interventional

A Study of the Efficacy (Effectiveness) of Paliperidone Palmitate in the Prevention of Recurrence of the Symptoms of Schizophrenia.

NCT00111189
View directory record Official record
Conditions
Schizophrenia
Interventions
Placebo, Paliperidone Palmitate
Drug
Lead sponsor
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Industry
Eligibility
18 Years to 65 Years
Enrollment
414 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
18
States / cities
Little Rock, Arkansas • Cerritos, California • Santa Ana, California + 15 more
Source: ClinicalTrials.gov public record
Updated Jun 19, 2014 · Synced Sep 10, 2026, 4:32 PM EDT
Completed Phase 3 Interventional Results available

Standard Lipid Therapy vs IVFE Minimization for Prevention of PNALD

NCT02357576
View directory record Official record
Conditions
Cholestasis
Interventions
Intralipid 20% I.V. Fat Emulsion
Drug
Lead sponsor
University of Michigan
Other
Eligibility
Up to 1 Year
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
5
States / cities
Aurora, Colorado • Gainesville, Florida • Ann Arbor, Michigan + 2 more
Source: ClinicalTrials.gov public record
Updated Dec 16, 2020 · Synced Sep 10, 2026, 4:32 PM EDT
Terminated Not applicable Interventional Results available

Intravenous Fat Emulsions and Premature Infants

NCT01096446
View directory record Official record
Conditions
Hypertriglyceridemia, Hyperglycemia
Interventions
Intravenous Fat Emulsions
Drug
Lead sponsor
OSF Healthcare System
Other
Eligibility
1 Day to 2 Days
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Peoria, Illinois
Source: ClinicalTrials.gov public record
Updated Nov 19, 2014 · Synced Sep 10, 2026, 4:32 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

The Mixed Meal Challenge Study

NCT05087823
View directory record Official record
Conditions
Cardiovascular Diseases, Hyperlipidemias
Interventions
Lipid Challenge, Glucose Challenge, Mixed Meal Challenge
Dietary Supplement
Lead sponsor
Emory University
Other
Eligibility
18 Years to 50 Years
Enrollment
11 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Apr 30, 2023 · Synced Sep 10, 2026, 4:32 PM EDT
Recruiting Phase 1Phase 2 Interventional Accepts healthy volunteers

Investigating Whether Acute Elevation of Fatty Acid Levels Alters Cerebral Glucose Transport and Metabolism

NCT04328337
View directory record Official record
Conditions
Obesity
Interventions
Intralipid, 20% Intravenous Emulsion, Placebos
Drug
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years to 45 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2026
U.S. locations
2
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Mar 29, 2025 · Synced Sep 10, 2026, 4:32 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Insulin and Insulin Pulses During Fasting

NCT06424015
View directory record Official record
Conditions
PreDiabetes
Interventions
Intralipid and heparin, Saline
Other
Lead sponsor
Mayo Clinic
Other
Eligibility
25 Years to 65 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2027
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Sep 30, 2025 · Synced Sep 10, 2026, 4:32 PM EDT
Terminated Phase 4 Interventional Results available

Safety and Efficacy Study to Compare Smoflipid and Intralipid 20% in Pediatric Patients of 3 Months to 16 Years of Age

NCT03563222
View directory record Official record
Conditions
Malnutrition, Child
Interventions
Smoflipid, Intralipid, 20%
Drug
Lead sponsor
Fresenius Kabi
Industry
Eligibility
3 Months to 16 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 11, 2022 · Synced Sep 10, 2026, 4:32 PM EDT
Completed Phase 4 Interventional Results available

Pediatric Study to Evaluate Risk of Developing Essential Fatty Acid Deficiency When Receiving Clinolipid or Standard-of-Care Lipid Emulsion (Part A)

NCT04555044
View directory record Official record
Conditions
Essential Fatty Acid Deficiency (EFAD)
Interventions
Clinolipid, Intralipid
Drug
Lead sponsor
Baxter Healthcare Corporation
Industry
Eligibility
0 Years to 17 Years
Enrollment
101 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
9
States / cities
Mobile, Alabama • New Haven, Connecticut • Orlando, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Dec 26, 2023 · Synced Sep 10, 2026, 4:32 PM EDT
Completed Not applicable Interventional

Long-Term Nutritional Support in Patients With the Acquired Immunodeficiency Syndrome: Comparison of Liposyn III 2 Percent With Liposyn II 20 Percent

NCT00002029
View directory record Official record
Conditions
HIV Infections
Interventions
Fat Emulsion 2%, Fat Emulsion 20%
Drug
Lead sponsor
Abbott
Industry
Eligibility
18 Years to 60 Years
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
2
States / cities
Miami, Florida • East Orange, New Jersey
Source: ClinicalTrials.gov public record
Updated Feb 19, 2009 · Synced Sep 10, 2026, 4:32 PM EDT
Withdrawn Phase 3 Interventional

Clevidipine vs Placebo or Standard of Care for Dyspnea and Blood Pressure Control in AHF

NCT04592380
View directory record Official record
Conditions
Dyspnea, Hypertension, Acute Heart Failure
Interventions
Stage 1: Clevidipine (double-blinded), Stage 1: Placebo (double-blinded), Stage 2: Clevidipine (open-label), Stage 2: Standard of Care (open-label)
Drug
Lead sponsor
The Medicines Company
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
9
States / cities
Montgomery, Alabama • Tucson, Arizona • St Louis, Missouri + 5 more
Source: ClinicalTrials.gov public record
Updated Oct 18, 2020 · Synced Sep 10, 2026, 4:32 PM EDT
Completed Phase 2 Interventional Results available

Early Supplementation of Enteral Microlipid With and Without Fish Oil in Premature Infants With Enterostomies

NCT01674478
View directory record Official record
Conditions
Prematurity, Intestine Perforation, Necrotizing Enterocolitis (NEC), Short Bowel Syndrome (SBS)
Interventions
Microlipid with fish oil, Microlipid
Dietary Supplement
Lead sponsor
Wake Forest University
Other
Eligibility
1 Day to 2 Months
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Dec 3, 2018 · Synced Sep 10, 2026, 4:32 PM EDT
Completed Phase 3 Interventional Results available

Study of Paliperidone Palmitate 3 Month and 1 Month Formulations for the Treatment of Patients With Schizophrenia

NCT01515423
View directory record Official record
Conditions
Schizophrenia
Interventions
PP3M 175 mg eq., PP3M 263 mg eq., PP3M 350 mg eq., PP3M 525 mg eq., Placebo (20% Intralipid), PP1M 50 mg eq., PP1M 75 mg eq., PP1M 100 mg eq., PP1M 150 mg eq.
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 70 Years
Enrollment
1,429 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
24
States / cities
Little Rock, Arkansas • Glendale, California • Long Beach, California + 21 more
Source: ClinicalTrials.gov public record
Updated May 1, 2016 · Synced Sep 10, 2026, 4:32 PM EDT
Not yet recruiting Phase 2 Interventional

A Phase 2 Study of Methylene Blue Photodynamic Therapy for Treatment of Breast Abscesses

NCT07179003
View directory record Official record
Conditions
Breast Abscess
Interventions
Standard of care breast abscess drainage, Methylene Blue, Lipid Emulsion, Insertion of optical fiber, Laser illumination, Photodynamic therapy
Procedure · Drug · Device
Lead sponsor
University of Rochester
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2027 – 2032
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Aug 18, 2026 · Synced Sep 10, 2026, 4:32 PM EDT
Completed Phase 3 Interventional Results available

Comparison of Smoflipid to Soy-based Lipid Reduction for Cholestasis Prevention in Surgical Neonates

NCT03387579
View directory record Official record
Conditions
Cholestasis of Parenteral Nutrition
Interventions
Smoflipid 20% Lipid Emulsion for Injection, Intralipid, 20% Intravenous Emulsion
Drug
Lead sponsor
Indiana University
Other
Eligibility
Not listed
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Jul 29, 2025 · Synced Sep 10, 2026, 4:32 PM EDT
Withdrawn Phase 1 Interventional Accepts healthy volunteers

Neuroimmune Mechanisms in Obesity

NCT05553405
View directory record Official record
Conditions
Obesity
Interventions
Intralipid Infusion
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years to 55 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2033
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jun 17, 2023 · Synced Sep 10, 2026, 4:32 PM EDT
Active, not recruiting Phase 4 Interventional Accepts healthy volunteers

Intralipid® 20% for Reversal of Local Anesthetics

NCT03968822
View directory record Official record
Conditions
Anesthesia, Local
Interventions
Lidocaine 2%, Lidocaine 1%, Bupivacaine 0.25%, Bupivacaine 0.5%, Intralipid, 20% Intravenous, Saline intravenously, Saline
Drug · Other
Lead sponsor
Hospital for Special Surgery, New York
Other
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2026
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 7, 2025 · Synced Sep 10, 2026, 4:32 PM EDT
Completed Not applicable Interventional

A Comparison of Two Types of Injected Nutritional Supplements in Patients With AIDS and Pneumocystis Carinii Pneumonia (PCP)

NCT00002275
View directory record Official record
Conditions
HIV Infections
Interventions
Fat Emulsion 2%, Fat Emulsion 20%
Drug
Lead sponsor
Abbott
Industry
Eligibility
18 Years to 60 Years
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
East Orange, New Jersey
Source: ClinicalTrials.gov public record
Updated Feb 19, 2009 · Synced Sep 10, 2026, 4:32 PM EDT
Completed Phase 3 Interventional Results available

A Study of Paliperidone Palmitate 3 Month Formulation for the Treatment of Patients With Schizophrenia

NCT01529515
View directory record Official record
Conditions
Schizophrenia
Interventions
PP3M 175 mg eq., PP3M 263 mg eq., PP3M 350 mg eq., PP3M 525 mg eq., Placebo (20% Intralipid emulsion)
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 70 Years
Enrollment
509 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
15
States / cities
Little Rock, Arkansas • San Fran Cisco, California • Washington D.C., District of Columbia + 12 more
Source: ClinicalTrials.gov public record
Updated May 10, 2016 · Synced Sep 10, 2026, 4:32 PM EDT
Terminated Phase 3 Interventional Results available

Progesterone for the Treatment of Traumatic Brain Injury III

NCT00822900
View directory record Official record
Conditions
Traumatic Brain Injury
Interventions
Progesterone, Placebo
Drug
Lead sponsor
David Wright
Other
Eligibility
18 Years and older
Enrollment
882 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
36
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Tuscon, Arizona + 26 more
Source: ClinicalTrials.gov public record
Updated Jan 19, 2016 · Synced Sep 10, 2026, 4:32 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Mechanism Underlying Beta-cell Failure in Obese African Americans With History of Hyperglycemic Crises

NCT00753142
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Intralipid 20%, Glucose infusion
Drug
Lead sponsor
Emory University
Other
Eligibility
18 Years to 65 Years
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2009
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Oct 11, 2018 · Synced Sep 10, 2026, 4:32 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

FFA Hypertension and Inflammation in Lean and Obese Subjects

NCT00721617
View directory record Official record
Conditions
Diabetes, Hypertension, Obesity
Interventions
Intralipid 20%, Normal Saline, Oral fat load
Other
Lead sponsor
Emory University
Other
Eligibility
18 Years to 65 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2011
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Jul 26, 2015 · Synced Sep 10, 2026, 4:32 PM EDT
Terminated Phase 3 Interventional Results available

Phase 3 Study to Compare Safety and Efficacy of Smoflipid 20% to Intralipid 20% in Hospitalized Neonates and Infants

NCT02579265
View directory record Official record
Conditions
Hospitalized Neonates and Infants, Expected to Require Parenteral Nutrition for 28 Days
Interventions
Smoflipid 20% (investigational lipid for parenteral nutrition), Intralipid® 20%
Drug
Lead sponsor
Fresenius Kabi
Industry
Eligibility
0 Weeks and older
Enrollment
204 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
13
States / cities
Palo Alto, California • San Diego, California • New Haven, Connecticut + 8 more
Source: ClinicalTrials.gov public record
Updated Jan 4, 2022 · Synced Sep 10, 2026, 4:32 PM EDT
Completed Phase 1 Interventional

Safety and Feasibility Study of Methylene Blue Photodynamic Therapy to Sterilize Deep Tissue Abscess Cavities

NCT02240498
View directory record Official record
Conditions
Abscess
Interventions
Methylene Blue, 20% I.V. Fat Emulsion, Insertion of optical fiber, Laser illumination, 5 minutes, Laser illumination, 10 minutes, Laser illumination, 15 minutes, Laser illumination, 20 minutes, Laser illumination, 25 minutes, Laser illumination, 30 minutes, Optical spectroscopy measurement
Drug · Device
Lead sponsor
University of Rochester
Other
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2023
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Apr 6, 2026 · Synced Sep 10, 2026, 4:32 PM EDT